For example, silencing of RPL35A can inhibit the malignant behaviour of gastric cancer cells by regulating the expression level of the phosphorylated kinase [10]; LncRNA NB1 binding to RPL35A can promote neuroblastoma development and metastasis [11]; up‐regulation of RPL35A can reduce the sensitivity of cancer cells to radiotherapy and chemotherapy [12]; silencing of RPL35A can inhibit the progression of ovarian cancer by inhibiting the binding of YY1 and CTCF promoter [13]. Here, RPL35A is linked to cancer.